The Role of Efflux Pump Inhibitor in Bacterial Multidrug Resistance
A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Mechanism and Evolution of Antibiotic Resistance".
Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 43528
Special Issue Editor
Interests: efflux systems of pathogenic bacteria; efflux pump inhibitors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Efflux pumps are protein constituents of all bacterial plasma membranes, and can recognize and extrude toxic compounds to the environment. The over-expression of these pumps is one of the hallmarks of the frequent failure of antimicrobial chemotherapy. For this reason the inhibition of efflux pumps could be an effective strategy to overcome multidrug resistance. Efflux pump inhibitors (EPIs) alone or in combination could restore the sensitivity of resistant strains by increasing the intracellular concentration of antibiotics and decreasing the level of intrinsic resistance. Concerning the chemical nature of EPIs, there are compounds from natural (plant) sources, semi-synthetic derivatives of existing EPIs, and fully synthetic EPIs as well.
This Special Issue of Antibiotics invites both reviews and original articles that consider efflux pump inhibitors as challenging tools to overcome multidrug resistance in bacteria.
Dr. Gabriella Spengler
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multidrug resistance
- multidrug efflux pump
- efflux pump inhibitor (EPI)
- accumulation assay
- efflux assay
- fluorochromes
- ethidium bromide
- quorum sensing
- biofilm
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.